These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32684582)

  • 21. Multi-gene mutation metastatic castrate-resistant prostate cancer.
    Christy J; Kandah E; Kesari K; Singh T
    BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34301684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
    Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
    Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
    Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case of metastatic prostate adenocarcinoma to an inguinal lymph node.
    Komeya M; Sahoda T; Sugiura S; Sawada T; Kitami K
    Cent European J Urol; 2012; 65(2):96-7. PubMed ID: 24578940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recrudescent prostate cancer with a low serum PSA level and a high serum CEA level treated with docetaxel : a case report].
    Fujita M; Goto T; Uchida K; Saiki S; Arima R
    Hinyokika Kiyo; 2013 Mar; 59(3):183-8. PubMed ID: 23633635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy.
    Shirotake S; Umezawa Y; Okabe T; Kaneko G; Kanao K; Nishimoto K; Oyama M
    Transl Androl Urol; 2020 Apr; 9(2):819-823. PubMed ID: 32420190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Complete remission of prostate cancer after LH-RH agonist neoadjuvant therapy: a case report].
    Furuse H; Ishikawa A; Masuda H; Ushiyama T; Suzuki K; Fujita K
    Hinyokika Kiyo; 1995 Jun; 41(6):485-8. PubMed ID: 7645458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Predictor analysis of PSA response of docetaxel combined with prednisone in the treatment of metastatic castration resistant prostate cancer].
    Yang KW; Yu W; Song Y; Huang LH; Han WK; He ZS; Jin J; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Aug; 47(4):592-6. PubMed ID: 26284391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer.
    Nakano M; Shoji S; Higure T; Kawakami M; Tomonaga T; Terachi T; Uchida T
    Mol Clin Oncol; 2016 Jun; 4(6):942-946. PubMed ID: 27284427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
    Autio KA; Dreicer R; Anderson J; Garcia JA; Alva A; Hart LL; Milowsky MI; Posadas EM; Ryan CJ; Graf RP; Dittamore R; Schreiber NA; Summa JM; Youssoufian H; Morris MJ; Scher HI
    JAMA Oncol; 2018 Oct; 4(10):1344-1351. PubMed ID: 29978216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
    Hussain A; Dawson N; Amin P; Naslund M; Engstrom C; Chen T
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):22-31. PubMed ID: 11685725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.
    Uehara S; Yuasa T; Fujii Y; Yano A; Yamamoto S; Masuda H; Fukui I; Yonese J
    BMC Res Notes; 2015 Aug; 8():335. PubMed ID: 26242866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
    BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Marked effectiveness of the LH-RH analogue in a case of prostate cancer with large lymph node metastasis].
    Takezawa Y; Ohtake N; Nakano K; Uchida T; Okamura K; Yamanaka H
    Hinyokika Kiyo; 1994 Aug; 40(8):721-4. PubMed ID: 7942372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervical lymphadenopathy as initial presentation of metastatic prostate cancer: A retrospective study of five cases and literature review.
    Liu Y; Dai Z; Hao J; Wang L; Liu Z
    Front Surg; 2023; 10():1081951. PubMed ID: 36793314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer with supraclavicular lymphadenopathy and bulky abdominal tumor.
    Kosugi S; Mizumachi S; Kitajima A; Igarashi T; Hamada T; Kaya H; Kurihara K; Ogasawara K; Sakata H; Yamamoto M; Nagamine M; Yamazaki H
    Intern Med; 2007; 46(14):1135-8. PubMed ID: 17634715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.